Bolt Biotherapeutics, Inc. BOLT
6.57 USD +0.33 (+5.29%)
At closeNov 3, 2026, 4:00 PM EST
6.10 -0.47 -7.15%
After hours · Nov 3, 4:00 PM ET
6.11 Day range 6.74
3.10 52-week range 7.78
- YTD
- +20.11%
- 1 year
- +17.74%
Analyst view
Price target (mean) 1.75 -73.4% downside
Now 6.57
- Target (low)
- 1.50
- Target (mean)
- 1.75
- Target (high)
- 2.00
Ratings (0m) 4 0 buy · 4 hold · 0 sell
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.36 – -0.34 | -0.47 | +25.5% | 790.00K | -62.2% | 2 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 400.00K | -92.4% | 0 |
| Current year | -1.50 | -1.57 – -1.43 | -1.83 | +18.0% | 8.48M | +7.7% | 2 |
| Next year | -0.89 | -0.94 – -0.84 | -1.50 | +40.7% | 3.41M | -59.8% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 15, 2024 | Leerink Partners | Downgrade | Outperform | Market Perform |
| May 15, 2024 | Jones Trading | Downgrade | Buy | Hold |
| May 15, 2024 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 15, 2024 | Guggenheim | Downgrade | Buy | Neutral |
| May 15, 2024 | Stifel | Downgrade | Buy | Hold |
| Mar 22, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 3, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 26, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| May 12, 2023 | SVB Leerink | Upgrade | Market Perform | Outperform |
| May 12, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 30, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 24, 2023 | Morgan Stanley | Maintained | — | Equal-Weight |
| Oct 4, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Aug 11, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| May 17, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jan 6, 2022 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Nov 10, 2021 | SVB Leerink | Maintained | — | Outperform |
| Aug 16, 2021 | SVB Leerink | Maintained | — | Outperform |
| May 17, 2021 | SVB Leerink | Maintained | — | Outperform |
| Apr 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Mar 2, 2021 | Stifel | Initiated | — | Buy |
| Mar 2, 2021 | Guggenheim | Initiated | — | Buy |
| Mar 2, 2021 | Morgan Stanley | Initiated | — | Overweight |
| Mar 2, 2021 | SVB Leerink | Initiated | — | Outperform |